Jaguar Health Receives Nasdaq Delisting Notice, Citing Prior Reverse Splits; Company Plans Appeal
JAGX is trading near its 52-week low of $0.56 (3.7% above the low) on light trading volume (0.1× avg).
Summary
Jaguar Health, Inc. received a delisting notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement and is ineligible for a standard compliance period due to prior reverse stock splits. The company intends to appeal the decision.
Key Events · Corporate Governance and Compliance · JAGX
-
Nasdaq Delisting Notice Received
On March 5, 2026, Jaguar Health, Inc. received a notification from Nasdaq's Listing Qualifications Department, stating that the company is no longer in compliance with the minimum $1.00 bid price requirement (Rule 5550(a)(2)) as its common stock traded below this threshold for 30 consecutive business days.
-
Ineligibility for Standard Compliance Period
The notice further specified that the company is not eligible for any standard compliance period under Nasdaq Listing Rule 5810(c)(3)(A) because it effected one or more reverse stock splits with a cumulative ratio of 250 shares or more to one over the prior two-year period.
-
Company Plans Appeal
Jaguar Health intends to timely request an appeal before a Hearings Panel by March 12, 2026. This request will automatically stay any further suspension or delisting action by Nasdaq pending the conclusion of the hearing process, though there is no assurance of a favorable outcome.
Analysis · JAGX · Life Sciences
Jaguar Health, Inc. has received a critical delisting notice from Nasdaq due to its common stock trading below the $1.00 minimum bid price for 30 consecutive business days. This situation is particularly severe as the company is ineligible for the standard compliance period, a direct consequence of having executed one or more reverse stock splits with a cumulative ratio of 250 shares or more to one within the prior two-year period. This indicates a persistent struggle to maintain its listing and suggests that previous attempts to boost share price through reverse splits have not provided a lasting solution. While the company intends to appeal the decision, there is no guarantee that the Panel will grant continued listing or that Jaguar Health will be able to regain and maintain compliance. This event significantly increases the risk profile for investors, highlighting ongoing challenges with valuation and market perception, especially as the stock trades near its 52-week low.
At the time of this filing, JAGX was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.56 to $15.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.